GT Biopharma (GTBP) Accumulated Expenses (2010 - 2026)

GT Biopharma (GTBP) has reported Accumulated Expenses for 17 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 91.08% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 91.08% YoY), while the FY2025 annual figure was $1.6 million, down 13.19% from the prior year.
• Accumulated Expenses improved to $2.2 million in Q1 2026 per GTBP's latest filing, from $1.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $2.2 million in Q1 2026 and bottomed at $400000.0 in Q3 2025.
• Historically, Accumulated Expenses has averaged $1.2 million across 5 years, with a median of $1.2 million in 2022.
• Annual changes were most pronounced in 2022 — Accumulated Expenses surged 105.21% — and 2025, when it sank 78.59%.
• GT Biopharma's Accumulated Expenses stood at $1.7 million in 2022, then declined by 28.4% to $1.2 million in 2023, then surged by 50.38% to $1.8 million in 2024, then declined by 13.19% to $1.6 million in 2025, then jumped by 38.65% to $2.2 million in 2026.
• Business Quant data shows GTBP's Accumulated Expenses at $2.2 million in Q1 2026, $1.6 million in Q4 2025, and $400000.0 in Q3 2025.